Glaukos, an ophthalmic medical technology and pharmaceutical company, completed the acquisition of Avedro, a leading hybrid ophthalmic pharmaceutical and medical technology company focused on treating corneal disease and disorders. For each share of Avedro common stock they own, Avedro shareholders received an exchange ratio equivalent of 0.365 shares of Glaukos stock. Glaukos owns 85% of the combined company, with Avedro shareholders own the remaining 15%. “This transaction pairs two highly complementary, hybrid pharma and device organizations, combining Avedro’s novel bio-activated pharmaceutical solutions and R&D capabilities with Glaukos’ global commercial scale, proven market-building and shared reimbursement expertise, and extensive clinical and regulatory infrastructure," Thomas Burns, Glaukos President and CEO. As a result of the acquisition’s close, Avedro’s common stock will now cease to trade on the Nasdaq.